Wells Fargo & Company MN Has $2.21 Million Stake in Tandem Diabetes Care, Inc. (NASDAQ:TNDM)

Wells Fargo & Company MN raised its holdings in shares of Tandem Diabetes Care, Inc. (NASDAQ:TNDM - Free Report) by 35.8% in the 4th quarter, according to its most recent 13F filing with the SEC. The fund owned 61,255 shares of the medical device company's stock after acquiring an additional 16,163 shares during the period. Wells Fargo & Company MN owned approximately 0.09% of Tandem Diabetes Care worth $2,206,000 at the end of the most recent reporting period.

A number of other large investors also recently made changes to their positions in the stock. Vanguard Group Inc. increased its holdings in Tandem Diabetes Care by 1.1% in the fourth quarter. Vanguard Group Inc. now owns 7,440,005 shares of the medical device company's stock valued at $267,989,000 after purchasing an additional 77,451 shares during the last quarter. GW&K Investment Management LLC raised its position in shares of Tandem Diabetes Care by 18.0% in the 4th quarter. GW&K Investment Management LLC now owns 2,123,488 shares of the medical device company's stock valued at $76,488,000 after acquiring an additional 323,674 shares during the period. Stephens Investment Management Group LLC boosted its stake in Tandem Diabetes Care by 22.1% during the 4th quarter. Stephens Investment Management Group LLC now owns 1,555,809 shares of the medical device company's stock worth $56,040,000 after acquiring an additional 281,327 shares during the last quarter. Geode Capital Management LLC grew its holdings in Tandem Diabetes Care by 0.5% during the fourth quarter. Geode Capital Management LLC now owns 1,533,828 shares of the medical device company's stock valued at $55,261,000 after purchasing an additional 8,012 shares during the period. Finally, Paradice Investment Management LLC increased its stake in Tandem Diabetes Care by 5.9% in the fourth quarter. Paradice Investment Management LLC now owns 956,407 shares of the medical device company's stock valued at $34,450,000 after purchasing an additional 52,966 shares in the last quarter.

Analyst Upgrades and Downgrades

TNDM has been the topic of a number of recent analyst reports. Morgan Stanley cut shares of Tandem Diabetes Care from an "overweight" rating to an "equal weight" rating and reduced their price target for the stock from $45.00 to $22.00 in a research report on Wednesday, March 5th. Barclays cut their target price on Tandem Diabetes Care from $60.00 to $53.00 and set an "overweight" rating on the stock in a research note on Friday, February 28th. Wells Fargo & Company reissued an "equal weight" rating and set a $22.00 price target (down from $38.00) on shares of Tandem Diabetes Care in a research report on Monday, March 3rd. Canaccord Genuity Group reiterated a "buy" rating and set a $63.00 price objective on shares of Tandem Diabetes Care in a research note on Wednesday, February 26th. Finally, The Goldman Sachs Group reduced their price objective on shares of Tandem Diabetes Care from $42.00 to $24.00 and set a "neutral" rating for the company in a research report on Monday, March 3rd. Eight research analysts have rated the stock with a hold rating and nine have assigned a buy rating to the company. Based on data from MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and an average price target of $41.69.

Insider Activity

In other Tandem Diabetes Care news, COO Jean-Claude Kyrillos purchased 10,538 shares of the company's stock in a transaction on Friday, March 7th. The shares were purchased at an average cost of $18.12 per share, with a total value of $190,948.56. Following the completion of the purchase, the chief operating officer now owns 10,538 shares in the company, valued at $190,948.56. This represents a ∞ increase in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. 1.90% of the stock is owned by company insiders.

Tandem Diabetes Care Trading Up 16.4 %

NASDAQ:TNDM traded up $2.76 on Thursday, reaching $19.61. 1,144,467 shares of the stock traded hands, compared to its average volume of 1,505,223. The company has a current ratio of 2.90, a quick ratio of 2.32 and a debt-to-equity ratio of 1.29. Tandem Diabetes Care, Inc. has a 1-year low of $15.75 and a 1-year high of $53.69. The company's 50 day moving average is $19.30 and its 200-day moving average is $28.87. The firm has a market capitalization of $1.31 billion, a price-to-earnings ratio of -10.16 and a beta of 1.52.

Tandem Diabetes Care (NASDAQ:TNDM - Get Free Report) last posted its quarterly earnings data on Wednesday, April 30th. The medical device company reported ($0.67) earnings per share for the quarter, missing the consensus estimate of ($0.60) by ($0.07). The firm had revenue of $234.42 million for the quarter, compared to analyst estimates of $220.19 million. Tandem Diabetes Care had a negative return on equity of 44.19% and a negative net margin of 14.84%. The company's quarterly revenue was up 22.3% compared to the same quarter last year. During the same quarter last year, the company earned ($0.65) earnings per share. Equities research analysts anticipate that Tandem Diabetes Care, Inc. will post -1.68 EPS for the current fiscal year.

About Tandem Diabetes Care

Tandem Diabetes Care, Inc, a medical device company, designs, develops, and commercializes technology solutions for people living with diabetes in the United States and internationally. The company's flagship product is the t:slim X2 insulin delivery system, a pump platform for managing insulin delivery and display continuous glucose monitoring sensor information directly on the pump home screen; and Tandem Mobi insulin pump, an automated insulin delivery system.